|
1
|
Suliburska J, Bogdanski P, Gajewska E,
Kalmus G, Sobieska M and Samborski W: The association of insulin
resistance with serum osteoprotegerin in obese adolescents. J
Physiol Biochem. 69:847–853. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
de Ciriza Perez C Villacampa:
Osteoprotegerin: A promising biomarker in the metabolic syndrome -
New perspectives. Biochem Anal Biochem. 5:1–3. 2016.
|
|
3
|
Fuentes E, Fuentes F, Vilahur G, Badimon L
and Palomo I: Mechanisms of chronic state of inflammation as
mediators that link obese adipose tissue and metabolic syndrome.
Mediators Inflamm. 2013:1365842013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Monseu M, Dubois S, Boursier J, Aubé C,
Gagnadoux F, Lefthériotis G and Ducluzeau PH: Osteoprotegerin
levels are associated with liver fat and liver markers in
dysmetabolic adults. Diabetes Metab. 42:364–367. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Docea AO, Vassilopoulou L, Fragou D,
Arsene AL, Fenga C, Kovatsi L, Petrakis D, Rakitskii VN, Nosyrevh
AE, Izotovh BN, et al: CYP polymorphisms and pathological
conditions related to chronic exposure to organochlorine
pesticides. Toxicol Rep. 4:335–341. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Drăgoi CM, Nicolae AC, Grigore C,
Dinu-Pîrvu CE and Arsene AL: Characteristics of glucose homeostasis
and lipidic profile in a hamster metabolic syndrome model, after
the co-administration of melatonin and irbesartan in a
multiparticulate pharmaceutical formulationThe Second International
Conference on Interdisciplinary Management of Diabetes Mellitus and
its Complications, INTERDIAB 2016. 3–5–March. Diabetes Mellitus as
Cardiovascular Disease, Ed.Niculescu, Bucharest: pp. 221–229.
2016;
|
|
7
|
Hernández AF, Parrón T, Tsatsakis AM,
Requena M, Alarcón R and López-Guarnido O: Toxic effects of
pesticide mixtures at a molecular level: Their relevance to human
health. Toxicology. 307:136–145. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mrema EJ, Rubino FM, Brambilla G, Moretto
A, Tsatsakis AM and Colosio C: Persistent organochlorinated
pesticides and mechanisms of their toxicity. Toxicology. 307:74–88.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Aguilera AA, Diaz GH, Barcelata ML,
Guerrero OA and Ros RM: Effects of fish oil on hypertension, plasma
lipids, and tumor necrosis factor-alpha in rats with
sucrose-induced metabolic syndrome. J Nutr Biochem. 15:350–357.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Klöting N, Blüher M and Klöting I: The
polygenetically inherited metabolic syndrome of WOKW rats is
associated with insulin resistance and altered gene expression in
adipose tissue. Diabetes Metab Res Rev. 22:146–154. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Augoulea A, Vrachnis N, Lambrinoudaki I,
Dafopoulos K, Iliodromiti Z, Daniilidis A, Varras M, Alexandrou A,
Deligeoroglou E and Creatsas G: Osteoprotegerin as a marker of
atherosclerosis in diabetic patients. Int J Endocrinol.
2013:1820602013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bernardi S, Fabris B, Thomas M, Toffoli B,
Tikellis C, Candido R, Catena C, Mulatero P, Barbone F, Radillo O,
et al: Osteoprotegerin increases in metabolic syndrome and promotes
adipose tissue proinflammatory changes. Mol Cell Endocrinol.
394:13–20. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bjerre M: Osteoprotegerin (OPG) as a
biomarker for diabetic cardiovascular complications. Springerplus.
2:6582013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gordin D, Soro-Paavonen A, Thomas MC,
Harjutsalo V, Saraheimo M, Bjerre M, Forsblom C, Flyvbjerg A and
Groop PH; FinnDiane Study Group, : Osteoprotegerin is an
independent predictor of vascular events in Finnish adults with
type 1 diabetes. Diabetes Care. 36:1827–1833. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Guo C, Hu F, Zhang S, Wang Y and Liu H:
Association between osteoprotegerin gene polymorphisms and
cardiovascular disease in type 2 diabetic patients. Genet Mol Biol.
36:177–182. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Montagnana M, Lippi G, Danese E and Guidi
GC: The role of osteoprotegerin in cardiovascular disease. Ann Med.
45:254–264. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Baud'huin M, Duplomb L, Teletchea S,
Lamoureux F, Ruiz-Velasco C, Maillasson M, Redini F, Heymann MF and
Heymann D: Osteoprotegerin: Multiple partners for multiple
functions. Cytokine Growth Factor Rev. 24:401–409. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen Z, Xue J, Shen T, Mu S and Fu Q:
Curcumin alleviates glucocorticoid-induced osteoporosis through the
regulation of the Wnt signaling pathway. Int J Mol Med. 37:329–338.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ndip A, Wilkinson FL, Jude EB, Boulton AJ
and Alexander MY: RANKL-OPG and RAGE modulation in vascular
calcification and diabetes: Novel targets for therapy.
Diabetologia. 57:2251–2260. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xiong J, Piemontese M, Thostenson JD,
Weinstein RS, Manolagas SC and O'Brien CA: Osteocyte-derived RANKL
is a critical mediator of the increased bone resorption caused by
dietary calcium deficiency. Bone. 66:146–154. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang Y, Shao J, Wang Z, Yang T, Liu S,
Liu Y, Fan X and Ye W: Aqueous extract of pomegranate seed
attenuates glucocorticoid-induced bone loss and hypercalciuria in
mice: A comparative study with alendronate. Int J Mol Med.
38:491–498. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bischoff-Ferrari HA and Staehelin HB:
Importance of vitamin D and calcium at older age. Int J Vitam Nutr
Res. 78:286–292. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
O'Brien EA, Williams JH and Marshall MJ:
Osteoprotegerin is produced when prostaglandin synthesis is
inhibited causing osteoclasts to detach from the surface of mouse
parietal bone and attach to the endocranial membrane. Bone.
28:208–214. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nan R, Grigorie D, Cursaru A, Șucaliuc A,
Drăguț R, Rusu E, Mușat M and Radulian G: Bisphosphonates - A good
choice for women with type 2 diabetes and postmenopausal
osteoporosis? Farmacia. 64:257–261. 2016.
|
|
25
|
Cima LN and Fica S: The use of anabolic
therapy in patients with betathalassemia major-induced osteoporosis
- review of the literature. Farmacia. 65:167–172. 2017.
|
|
26
|
Lee CJ, Wang JH, Chen ML, Yang CF, Chen YC
and Hsu BG: Serum osteoprotegerin is associated with arterial
stiffness assessed according to the cardio-ankle vascular index in
hypertensive patients. J Atheroscler Thromb. 22:304–312. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Pérez de Ciriza C, Moreno M, Restituto P,
Bastarrika G, Simón I, Colina I and Varo N: Circulating
osteoprotegerin is increased in the metabolic syndrome and
associates with subclinical atherosclerosis and coronary arterial
calcification. Clin Biochem. 47:272–278. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yu G, Ji X, Jin J and Bu S: Association of
serum and vitreous concentrations of osteoprotegerin with diabetic
retinopathy. Ann Clin Biochem. 52:232–236. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhu M, Fang X, Zhou S, Li W and Guan S:
Indirect co culture of vascular smooth muscle cells with bone
marrow mesenchymal stem cells inhibits vascular calcification and
downregulates the Wnt signaling pathways. Mol Med Rep.
13:5141–5148. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang ST, Xu JM, Wang M, Chen FL and Ding
G: Increased plasma osteoprotegerin concentrations in type 1
diabetes with albuminuria. Clin Nephrol. 79:192–198. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Borman P, Babaoğlu S, Gur G, Bingol S and
Bodur H: Bone mineral density and bone turnover in patients with
psoriatic arthritis. Clin Rheumatol. 27:443–447. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kanis JA, McCloskey EV, Johansson H,
Cooper C, Rizzoli R and Reginster JY: Scientific Advisory Board of
the European Society for Clinical and Economic Aspects of
Osteoporosis and Osteoarthritis (ESCEO) and the Committee of
Scientific Advisors of the International Osteoporosis Foundation
(IOF): European guidance for the diagnosis and management of
osteoporosis in postmenopausal women. Osteoporos Int. 24:23–57.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Christgau S, Rosenquist C, Alexandersen P,
Bjarnason NH, Ravn P, Fledelius C, Herling C, Qvist P and
Christiansen C: Clinical evaluation of the Serum CrossLaps One Step
ELISA, a new assay measuring the serum concentration of
bone-derived degradation products of type I collagen
C-telopeptides. Clin Chem. 44:2290–2300. 1998.PubMed/NCBI
|
|
34
|
Grădinaru D, Mitrea N, Margină D, Arsene
AL, Gruia V, Drăgoi C, Nicolae A, Borşa C and Gherasim P:
Evaluation of serum osteocalcin in eldery patients with type-2
diabetes mellitus. Farmacia. 57:331–338. 2009.
|
|
35
|
Hamann KL and Lane NE: Parathyroid hormone
update. Rheum Dis Clin North Am. 32:703–719. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Henriksen K, Karsdal MA and Martin TJ:
Osteoclast-derived coupling factors in bone remodeling. Calcif
Tissue Int. 94:88–97. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Starup-Linde J, Eriksen SA, Lykkeboe S,
Handberg A and Vestergaard P: Biochemical markers of bone turnover
in diabetes patients - a meta-analysis, and a methodological study
on the effects of glucose on bone markers. Osteoporos Int.
25:1697–1708. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kamineni V, Latha AP and Ramathulasi K:
Association between serum 25-hydroxyvitamin D levels and bone
mineral density in normal postmenopausal women. J Midlife Health.
7:163–168. 2016.PubMed/NCBI
|
|
39
|
Rasheed N Wael, Barbu CG, Florea S,
Branceanu G, Fica S, Mitrea N, Dragoi CM, Nicolae AC and Arsene AL:
Biochemical markers of calcium and bone metabolism in the
monitoring of osteoporosis treatment. Farmacia. 62:728–736.
2014.
|
|
40
|
Ohta H, Uemura Y, Nakamura T, Fukunaga M,
Ohashi Y, Hosoi T, Mori S, Sugimoto T, Itoi E, Orimo H, et al
Adequate Treatment of Osteoporosis (A-TOP) Research Group, : Serum
25-hydroxyvitamin D level as an independent determinant of quality
of life in osteoporosis with a high risk for fracture. Clin Ther.
36:225–235. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zugravu CA, Soptica F, Tarcea M and Cucu
A: Pertinence of vitamin D supplementation in the adult Romanian
population. Farmacia. 64:467–472. 2016.
|
|
42
|
Heaney RP: The vitamin D requirement in
health and disease. J Steroid Biochem Mol Biol. 97:13–19. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Holick MF: Vitamin D: A millenium
perspective. J Cell Biochem. 88:296–307. 2003. View Article : Google Scholar : PubMed/NCBI
|
